The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the UK version of the EU Market Abuse Regulation 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018, as amended and supplemented from time to time. Upon the publication of this announcement, this inside information is now considered to be in the public domain.
19 June 2024
IXICO plc
("IXICO" or the "Company")
New pharma client contract win valued in excess of £1m for a study of a Parkinsonian disorder
IXICO plc (AIM: IXI), the precision analytics company delivering intelligent insights in neuroscience, is pleased to announce that it has been contracted by a top five CRO on behalf of a new pharma client to provide its imaging biomarker services for a Phase 3 clinical trial for patients with a type of Parkinsonian disorder. The trial is due to run for just under 5 years and is worth in excess of £1m.
Giulio Cerroni, Chief Executive Officer of IXICO, commented:
"Following the new contract win announced on 23rd May in Alzheimer's Disease, we are delighted to be announcing the award of a contract from a new client to support the development of a promising treatment targeting a Parkinsonian disorder. We are pleased that our expertise in providing imaging analysis and radiological reads across clinical trials for a broadening range of neurodegenerative disorders, is increasingly recognised across the drug development industry and continues to attract new Sponsors seeking these expert services."
For further information please contact:
| IXICO plc | +44 (0) 20 3763 7499 | ||
| Giulio Cerroni, Chief Executive Officer Grant Nash, Chief Financial Officer |
| ||
|
|
| ||
| Cavendish Capital Markets Limited (Nominated Adviser and Sole Broker) | +44 (0) 20 7220 0500 | ||
| Giles Balleny / Dan Hodkinson (Corporate Finance) Nigel Birks/Harriet Ward (Corporate Broking) Michael F Johnson / Tamar Cranford Smith (Sales) |
| | |
About IXICO
IXICO is dedicated to delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's disease, Parkinson's disease and Alzheimer's disease. The Company's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience by supporting pharmaceutical companies across all phases of CNS clinical research. IXICO's goal is to be a leading advocate of artificial intelligence in medical image analysis.
IXICO has developed and deployed breakthrough data analytics, at scale, through its remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for the Company's pharmaceutical clients.
More information is available on www.IXICO.com and follow us on Twitter @IXICOnews
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.